Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608437 | 0.79 | KMT2A (0.41) | PIK3CDKMT2AACACBHDAC8KIF11 | |
| SCHEMBL28210909 | 0.79 | PIK3CD (0.38) | PIK3CDKMT2AACACBHDAC8KIF11 | |
| SCHEMBL299024 | 0.76 | — | — | |
| SCHEMBL5752803 | 0.75 | KMT2A (0.47) | PIK3CDKMT2AACACBHDAC8KIF11 | |
| SCHEMBL28296615 | 0.75 | KMT2A (0.41) | PIK3CDKMT2AACACBCSF1R | |
| SCHEMBL14953422 | 0.75 | KMT2A (0.38) | PIK3CDKMT2AACACBHDAC8IDO1 | |
| SCHEMBL2614311 | 0.75 | ACACB (0.52) | PIK3CDKMT2AACACBKIF11ABL1 | |
| Methyl Alcohol SCHEMBL28357518 | 0.74 | KMT2A (0.43) | PIK3CDKMT2AACACBHDAC8GRM4 | |
| SCHEMBL2170819 | 0.73 | — | — | |
| SCHEMBL24568233 | 0.72 | ACACB (0.47) | PIK3CDKMT2AACACBCSF1RKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112266828-A | Method for extracting essence from reed leaves | 张家界康华实业有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | UNIV CORNELL (US) | 2022-02-24 | — | — | US | disclosed |
| CN-112266828-A | Method for extracting essence from reed leaves | 张家界康华实业有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| CN-105061418-A | Precursor-aroma compound having sweet aroma and nut aroma as well as preparation method and application of precursor-aroma compound | CHINA TOBACCO CHUANYU IND CO | 2015-11-18 | — | — | CN | disclosed |
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7589118-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-09-15 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547724-B2 | IAP BIR domain binding compounds | AEGERA THERPEUTICS, INC. | 2009-06-16 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056073-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | PSMB1, PSMB3, PSMB11 | PIK3CD 2556/4885KMT2A 1292/4885ACACB 4421/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PIK3CD 1889/4885KMT2A 4686/4885ACACB 3892/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PIK3CD 1889/4885KMT2A 4686/4885ACACB 3892/4885 |
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | PIK3CD 208/4885KMT2A 2377/4885ACACB 941/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | PIK3CD 2272/4885KMT2A 4730/4885ACACB 4613/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | PIK3CD 377/4885KMT2A 1017/4885ACACB 692/4885 |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ITGA2B, ITGB1, ITGB5 | PIK3CD 2990/4885KMT2A 4150/4885ACACB 698/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | PIK3CD 2001/4885KMT2A 4661/4885ACACB 4068/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | PIK3CD 2556/4885KMT2A 1292/4885ACACB 4421/4885 |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | PIK3CD 2769/4885KMT2A 2941/4885ACACB 804/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | PIK3CD 3877/4885KMT2A 3232/4885ACACB 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.